Live Vital vs Apex MD
Live Vital labels a ten-week compounded protocol; Apex MD lists semaglutide with added ingredients. Match the preparation and supplied period before comparing costs.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Live Vital
Partner
$130/mo
The ten-week protocol total is more useful than the monthly headline. Both GLP-1 pages explicitly describe compounded injections. Confirm the prescribed supply, dispensing pharmacy and next charge; the protocol label does not establish that billing stops.
- The protocol total is published beside the rate
- The advertised protocol length is stated
- Product pages identify weekly injections
- The site describes physician review
- A ten-week protocol is priced as three months
- Renewal arrangements need clarification before purchase
- The refund policy contains unfinished policy text
- Compounding pharmacy is not named
Pick it for: Considering a ten-week label after checking supply and renewal
Not for: Anyone comparing advertised monthly figures at face value.
Apex MD
Editorial
$299/mo
Prices all four combinations: semaglutide at $299 injected and $349 orally, tirzepatide at $399 and $419. Expensive across the board, but one of the few sellers that will tell you the oral figure without an intake.
- No plan term — a month is a month
- Both molecules in both routes, each priced separately
- Prices published before the intake
- 51 jurisdictions
- Priced well above where this market sets compounded semaglutide
- The semaglutide injection contains additives with no trial behind the combination
- $50 to $100 route premium on top
- Compounding pharmacy is not named
Pick it for: Comparing month-to-month care and the added-ingredient preparation
Not for: Anyone who wants the molecule on its own, or a competitive rate.
Our verdict
Apex MD lists semaglutide compounded with NAD, B-12 and L-carnitine, with no published multi-month rate. That ingredient list alone does not establish evidence or results for the exact preparation. Live Vital explicitly describes compounded semaglutide and advertises a ten-week protocol. The label does not establish the vial quantity, dispensing schedule or whether another charge follows. Ask both providers which formulation, prescribed dose and supplied period the quote covers. Confirm Live Vital's renewal arrangement and cancellation terms before treating ten weeks as a billing endpoint.
What actually separates them
Live Vital and Apex MD differ on published price and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
Apex MD’s comparison figure is $169 higher than Live Vital’s — a 130% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $1,560 at Live Vital against $3,588 at Apex MD — a difference of $2,028. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| Live Vital | Apex MD | |
|---|---|---|
| Published price | $130/mo | $299/mo |
| Where you can use it | Confirm selected treatment eligibility | 51 jurisdictions |
What neither of them tells you
A comparison that only reports differences implies everything else is settled. Here it is not.
- Both sell a compounded drug and neither names the pharmacy that compounds it.
Before you choose either
The providers describe different service areas. Apex MD lists 1 that Live Vital does not list — DC. Confirm your location and selected medication directly. A provider-wide footprint does not establish every treatment’s availability.
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.